You are here: Industry Insights > Orphan Drug Designation

News List

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA prnasia
January 28, 2022
Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD)...
ImmunoForge Inc. receives U.S. FDA ODD for PF1801 prnasia
October 29, 2021
ImmunoForge (Co-CEOs Sung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801...
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma prnasia
April 27, 2020
CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on CARsgen's application for orphan designation of it
EMA grants orphan drug designation to AlloVir’s Viralym-M pharmaceutical-business-review
March 31, 2020
AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, announced it has been granted Orphan Drug Designation from the European Medicines Agency (EMA) for Viralym-M (ALVR105).
Alkindi granted Orphan Drug Designation in Australia and grant of second Alkindi patent in Australia firstwordpharma
April 25, 2019
Significant opportunity to address unmet medical need in paediatric adrenal insufficiency in Australia
OBI Pharma receives FDA ODD for OBI-3424 biospectrumasia
September 29, 2018
OBI-3424 is a first in class DNA alkylating cancer therapeutic agent targeting aldo-keto reductase 1C3 (AKR1C3) overexpressing cancers.
European Commission grants orphan drug designation to NeuroVive KL pharmaasia
December 22, 2017
The NeuroVive KL1333 programme targets oral treatment of Mitochondrial Myopathy, Encephalopathy, Lactic acidosis and Stroke-like episodes (MELA